Hudson Bay Capital Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Hudson Bay Capital Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-110,000	Closed	-$2.22M	–	1329
2021 Q3	$2.22M	Buy	110,000 +25,024	+29%	+$691K	0.03%	603
2021 Q2	$3.17M	Sell	84,976 -80,024	-48%	-$2.45M	0.04%	489
2021 Q1	$4.22M	Sell	165,000 -5,000	-3%	-$128K	0.05%	343
2020 Q4	$3.75M	Sell	170,000 -160,000	-48%	-$3.52M	0.04%	277
2020 Q3	$5.94M	Buy	330,000 +120,000	+57%	+$2.48M	0.09%	203
2020 Q2	$5.33M	Buy	+210,000	New	+$4.52M	0.09%	188

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.76B AUM 40.74% 1-Year Est. Return

Hudson Bay Capital Management's DRNA Position: Q4 2021 in Review

Hudson Bay Capital Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 110,000 shares — an estimated $2.22M sold.

Hudson Bay Capital Management first reported a position in DRNA in Q2 2020 and held it in 6 quarters. The position peaked at $5.94M in Q3 2020. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Hudson Bay Capital Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Hudson Bay Capital Management sold 110,000 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $2.22M.
Hudson Bay Capital Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2020 and held it in 6 quarters.
Hudson Bay Capital Management's Dicerna Pharmaceuticals, Inc. position peaked at $5.94M in Q3 2020.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Hudson Bay Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.